Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 4 SUPPL. 2, 2003, Pages

  Crane, Christopher H ^a   Mason, Kathy ^a   Janjan, Nora A ^a   Milas, Luka ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cyclooxygenase 2; Gemcitabine; Pancreatic cancer; Radiotherapy

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; GEMCITABINE;

ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DEHYDRATION; DRUG EFFICACY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; RADIATION DOSE;

ADENOCARCINOMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DEOXYCYTIDINE; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PANCREATIC NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RADIATION-SENSITIZING AGENTS; SULFONAMIDES;

EID: 0042575268     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200308002-00009     Document Type: Conference Paper

References (19)

1. Woolam GL. Cancer statistics, 2000: a benchmark for the new century. CA Cancer J Clin 2000;50:6.
2. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group. Ann Surg 1979;189:205-8.
3. Moertel CG, Frytak S, Hahn RT, et al. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981;48:1705-10.
4. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
5. Mason KA, Milas L, Hunter NR, et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 1999;44:1125-35.
6. Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999;59:107-14.
7. Joschko MA, Webster LK, Groves J, et al. Radioenhancement by gemcitabine with accelerated fractionated radiotherapy in a human tumor xenograft model. Radiat Oncol Investig 1997;5:62-71.
8. Lawrence T, Eisbruch A, Shewach D. Gemcitabine-mediated radiosensitization. Semin Oncol 1997;24(suppl):S724-8.
9. McGinn C, Shureiqi I, Robertson J, et al. A phase I trial of radiation dose escalation with full dose gemcitabine in patients with pancreatic cancer. Proc Am Soc Clin Oncol 1999;18:274a.
10. Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 2001;7:2246-53.
11. Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-FU-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002;52:1293-1302.
12. Mason KA, Komaki R, Cox JD, et al. Biology-based combined-modality radiotherapy: workshop report. Int J Radiat Oncol Biol Phys 2001;50:1079-89.
13. Koki A, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investig Drugs 1999;8:1623-38.
14. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 2001;11:290-9.
15. Milas L, Hanson WR. Eicosanoids and radiation. Eur J Cancer 1995;31A:1580-5.
16. Milas L, Kishi K, Hunter N, et al. Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 1999;91:1501-4.
17. Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000;60:1326-31.
18. Petersen C, Petersen S, Milas L, et al. Enhancement of intrinsic tumor cell radiosensitivity by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 2000;6:2513-20.
19. Crane CH, Janjan NA, Evans DB, et al. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 2001;29:9-18.